Related references
Note: Only part of the references are listed.Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology A Systematic Review and Quantitative Analysis
Bruno Kovic et al.
JAMA INTERNAL MEDICINE (2018)
Economics of Cancer Medicines: For Whose Benefit?
Bishal Gyawali et al.
NEW BIOETHICS-A MULTIDISCIPLINARY JOURNAL OF BIOTECHNOLOGY AND THE BODY (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
F. Bonnetain et al.
ANNALS OF ONCOLOGY (2017)
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Carl A. K. Borrebaeck
NATURE REVIEWS CANCER (2017)
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy
F. Perrone et al.
ANNALS OF ONCOLOGY (2016)
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Scott D. Ramsey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
Andrew Bottomley et al.
LANCET ONCOLOGY (2016)
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma
E. M. Hersh et al.
ANNALS OF ONCOLOGY (2015)
Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials
Fabio Efficace et al.
CANCER (2015)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
Takehito Shukuya et al.
LANCET ONCOLOGY (2015)
The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2015)
Unintended Consequences of Expensive Cancer Therapeutics-The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity The John Conley Lecture
Tito Fojo et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2014)
Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer
Jeffrey M. Peppercorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer
F. Joly et al.
ANNALS OF ONCOLOGY (2007)
Share Paper
